Related Experiment Video
Updated: Jul 17, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab-induced arrhythmia in a patient with lung adenocarcinoma: A case report
Jing Li1, Furong Zhang2, Yuanyuan Lu2
1Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rationale:
Cardiotoxicity is an important side effect of vascular endothelial growth factor inhibitors therapy in the treatment of cancer. Massive studies have shown bevacizumab-related hypertension, venous, and arterial thrombosis.
Patient Concerns:
A 56-year-old female patient was treated with bevacizumab monotherapy for lung adenocarcinoma. The patient was detected a poor R-wave increase with slight ST segment elevation in V1-V3 leads, and ventricular arrhythmia.
Diagnosis:
The incidental arrhythmia caused by bevacizumab was considered.
Interventions:
The patients received aspirin and amiodarone (0.2 g tid) to treat arrhythmia. After consultation with the cardiology department, the patient received a diagnostic coronary angiography. Coronary angiography showed 30% of the right coronary artery stenoses and no obvious organic stenosis in the left main artery, left anterior ascending, or left circumflex.
Outcomes:
The patient exhibited disappearance of chest tightness and rapid heartbeat after the treatment of amiodarone. Electrocardiogram monitoring results returning to normal.
Lessons:
This is the first reported case of bevacizumab-associated arrhythmia. It is advisable to consider the risk of arrhythmia in bevacizumab monotherapy or combines treatment.
Related Concept Videos
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiopulmonary Resuscitation IV: Pharmacological Management
Mechanism of Cardiac Arrhythmias

